Regencell Bioscience Shares Down 11.5% to $6.63
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 26 2026
0mins
Regencell Bioscience is down -11.5%, or -86c to $6.63.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regencell Bioscience Shares Surge 35% Amid Short Squeeze
- Short Squeeze Effect: Regencell Bioscience shares surged approximately 35% amid a significant short squeeze, with trading volume reaching about 2.18 million shares by 2:25 PM ET, far exceeding the average daily volume of 151,000 shares.
- Year-to-Date Decline: Despite today's notable increase, Regencell is down roughly 61% year-to-date, indicating ongoing pressure on the company that may affect investor confidence moving forward.
- Annual Return Drop: Over the past year, Regencell's stock has declined about 44%, reflecting long-term challenges that could lead investors to reassess the company's future growth potential.
- Increased Market Attention: This price volatility has drawn market attention to Regencell, prompting investors to closely monitor its subsequent performance and potential fundamental changes to make more informed investment decisions.
See More
Regencell Bioscience Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd., seeking damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting serious concerns over the company's compliance and operational transparency.
- Allegations of False Statements: The complaint alleges that during the class period, defendants made materially false and misleading statements and failed to disclose the true state of the company's business and compliance policies, potentially misleading investors and impacting their returns.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 23, 2026, indicating the legal team's commitment to protecting investor rights while emphasizing the proactive role investors can take in the legal process.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee arrangements, meaning investors do not incur upfront costs and only pay attorney fees upon successful recovery, thereby reducing the financial burden on investors.
See More
Regencell Bioscience Class Action Alert for Investors
- Class Action Notice: The Portnoy Law Firm advises investors of Regencell Bioscience Holdings Limited (NASDAQ: RGC) regarding a class action for those who purchased securities between October 28, 2024, and October 31, 2025, with a deadline to file a lead plaintiff motion by June 23, 2026.
- Market Manipulation Risks: The complaint alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and increasing the likelihood of regulatory scrutiny and enforcement actions.
- Rising Legal Costs: On October 31, 2025, Regencell revealed in an SEC filing that it received a subpoena from the U.S. Department of Justice due to recent market volatility, indicating potential significant legal costs and fines that may exceed any insurance coverage.
- Stock Price Plunge: Following this news, Regencell's ordinary share price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, highlighting the market's uncertainty about the company's future and a decline in investor confidence.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to potentially receive compensation without any out-of-pocket fees.
- Counsel Selection: Investors are encouraged to choose qualified counsel with a proven track record, as Rosen Law Firm is recognized for its success in securities class actions, having ranked No. 1 in 2017 for settlements according to ISS Securities Class Action Services.
- Case Background: The lawsuit alleges that Regencell made false or misleading statements during the class period, exposing investors to market manipulation and significant financial risks, along with potential regulatory scrutiny and legal repercussions affecting the company's reputation.
- Investor Losses: As the true details emerged, investors suffered damages, and Rosen Law Firm aims to secure compensation for affected investors, ensuring their rights are protected.
See More
Regencell Faces Class Action Lawsuit for Investor Rights
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting potential legal liabilities for the company.
- Allegations of False Statements: The lawsuit alleges that Regencell and its executives failed to disclose significant adverse facts regarding the company's operations and compliance policies, exposing investors to substantial financial risks and raising concerns about the company's transparency.
- Market Manipulation Risks: The lawsuit mentions that Regencell's stock was subject to market manipulation, resulting in increased volatility that not only undermined investor confidence but also could trigger further scrutiny from regulatory bodies.
- Investor Rights Protection: Investors must apply by June 23, 2026, to be appointed as lead plaintiffs in the lawsuit, underscoring the importance of this case in protecting investor rights, with the law firm offering free consultations to encourage more affected investors to participate.
See More
Multiple Companies Face Class Action Lawsuits
- LKQ Corporation Lawsuit: LKQ Corporation is facing a class action lawsuit for failing to disclose significant risks regarding customer losses and declining market share during the period from February 27, 2023, to July 23, 2025, with a lead plaintiff deadline of June 22, 2026, potentially impacting the company's reputation and stock price.
- Regencell Bioscience Lawsuit: Regencell Bioscience Holdings Limited is accused of failing to disclose market manipulation risks from October 28, 2024, to October 31, 2025, exposing investors to significant financial risks, with a lead plaintiff deadline of June 23, 2026, which may trigger regulatory scrutiny.
- Globant S.A. Lawsuit: Globant S.A. is under scrutiny for not disclosing decreasing demand and project cancellations in Latin America from February 15, 2024, to August 14, 2025, leading to investor losses, with a lead plaintiff deadline of June 23, 2026, which could negatively affect future performance.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors that they can contact the firm to discuss their legal rights if they suffered losses during the specified periods, which may influence their legal options and subsequent actions.
See More
Regencell Bioscience Shares Surge 35% Amid Short Squeeze
- Short Squeeze Effect: Regencell Bioscience shares surged approximately 35% amid a significant short squeeze, with trading volume reaching about 2.18 million shares by 2:25 PM ET, far exceeding the average daily volume of 151,000 shares.
- Year-to-Date Decline: Despite today's notable increase, Regencell is down roughly 61% year-to-date, indicating ongoing pressure on the company that may affect investor confidence moving forward.
- Annual Return Drop: Over the past year, Regencell's stock has declined about 44%, reflecting long-term challenges that could lead investors to reassess the company's future growth potential.
- Increased Market Attention: This price volatility has drawn market attention to Regencell, prompting investors to closely monitor its subsequent performance and potential fundamental changes to make more informed investment decisions.
See More
Regencell Bioscience Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd., seeking damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting serious concerns over the company's compliance and operational transparency.
- Allegations of False Statements: The complaint alleges that during the class period, defendants made materially false and misleading statements and failed to disclose the true state of the company's business and compliance policies, potentially misleading investors and impacting their returns.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 23, 2026, indicating the legal team's commitment to protecting investor rights while emphasizing the proactive role investors can take in the legal process.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee arrangements, meaning investors do not incur upfront costs and only pay attorney fees upon successful recovery, thereby reducing the financial burden on investors.
See More
Regencell Bioscience Class Action Alert for Investors
- Class Action Notice: The Portnoy Law Firm advises investors of Regencell Bioscience Holdings Limited (NASDAQ: RGC) regarding a class action for those who purchased securities between October 28, 2024, and October 31, 2025, with a deadline to file a lead plaintiff motion by June 23, 2026.
- Market Manipulation Risks: The complaint alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and increasing the likelihood of regulatory scrutiny and enforcement actions.
- Rising Legal Costs: On October 31, 2025, Regencell revealed in an SEC filing that it received a subpoena from the U.S. Department of Justice due to recent market volatility, indicating potential significant legal costs and fines that may exceed any insurance coverage.
- Stock Price Plunge: Following this news, Regencell's ordinary share price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, highlighting the market's uncertainty about the company's future and a decline in investor confidence.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to potentially receive compensation without any out-of-pocket fees.
- Counsel Selection: Investors are encouraged to choose qualified counsel with a proven track record, as Rosen Law Firm is recognized for its success in securities class actions, having ranked No. 1 in 2017 for settlements according to ISS Securities Class Action Services.
- Case Background: The lawsuit alleges that Regencell made false or misleading statements during the class period, exposing investors to market manipulation and significant financial risks, along with potential regulatory scrutiny and legal repercussions affecting the company's reputation.
- Investor Losses: As the true details emerged, investors suffered damages, and Rosen Law Firm aims to secure compensation for affected investors, ensuring their rights are protected.
See More
Regencell Faces Class Action Lawsuit for Investor Rights
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting potential legal liabilities for the company.
- Allegations of False Statements: The lawsuit alleges that Regencell and its executives failed to disclose significant adverse facts regarding the company's operations and compliance policies, exposing investors to substantial financial risks and raising concerns about the company's transparency.
- Market Manipulation Risks: The lawsuit mentions that Regencell's stock was subject to market manipulation, resulting in increased volatility that not only undermined investor confidence but also could trigger further scrutiny from regulatory bodies.
- Investor Rights Protection: Investors must apply by June 23, 2026, to be appointed as lead plaintiffs in the lawsuit, underscoring the importance of this case in protecting investor rights, with the law firm offering free consultations to encourage more affected investors to participate.
See More
Multiple Companies Face Class Action Lawsuits
- LKQ Corporation Lawsuit: LKQ Corporation is facing a class action lawsuit for failing to disclose significant risks regarding customer losses and declining market share during the period from February 27, 2023, to July 23, 2025, with a lead plaintiff deadline of June 22, 2026, potentially impacting the company's reputation and stock price.
- Regencell Bioscience Lawsuit: Regencell Bioscience Holdings Limited is accused of failing to disclose market manipulation risks from October 28, 2024, to October 31, 2025, exposing investors to significant financial risks, with a lead plaintiff deadline of June 23, 2026, which may trigger regulatory scrutiny.
- Globant S.A. Lawsuit: Globant S.A. is under scrutiny for not disclosing decreasing demand and project cancellations in Latin America from February 15, 2024, to August 14, 2025, leading to investor losses, with a lead plaintiff deadline of June 23, 2026, which could negatively affect future performance.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors that they can contact the firm to discuss their legal rights if they suffered losses during the specified periods, which may influence their legal options and subsequent actions.
See More
